Prof. Ping Zhang 张平
Chief Physician, Professor
Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical diagnosis and treatment of cervical, ovarian, endometrial, vaginal, and vulvar cancers. Specializes in complex surgeries for advanced ovarian cancer and fertility-sparing procedures for young patients with cervical cancer.
Dr. Zhang is a Chief Physician, Professor, and Ward Director at Zhejiang Cancer Hospital, with over 30 years of experience in gynecologic oncology. A graduate of Zhejiang University School of Medicine, Dr. Zhang serves as a master’s supervisor. Clinical expertise includes surgery and chemotherapy for gynecologic tumors, with a focus on patient quality of life.
Professional roles
- Vice Chair, Zhejiang Branch of Chinese Medical Association
- Designated Chair, Gynecologic Oncology Professional Committee, Zhejiang Anti-Cancer Association
- Member, Gynecologic Oncology Branch, Oncology Division, Chinese Medical Association
- Editorial Board Member, International Journal of Gynecology and Obstetrics; China Oncology; Journal of Oncology
Name order: in Chinese the family name comes first (Zhang Ping). Papers usually list the name as Ping Zhang or Zhang P.
Selected publications
74 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Food Chem, 2026 (first author): Tetramodal saccharin (SAC) sensing with a novel Ba-MOF: Leveraging SAC-induced PET effect and enhanced photocatalytic oxidase-mimicking activity. PubMed 42800093
- Mikrochim Acta, 2026 (first author): Post-synthetic modification strategy to a ratiometric fluorescent probe Fe-CAU-10-OH@Cou for trimodal detection of zineb in food samples. PubMed 42611112
- J Pharm Biomed Anal, 2024 (first author): Plasma-based near-infrared spectroscopy for early diagnosis of lung cancer. PubMed 39053095
- Apoptosis, 2024 (first author): A novel safer CD19CAR with shRNA interference of IFN-γ can reduce multiple cytokine levels without significantly compromising its killing efficacy. PubMed 38114800
- Apoptosis, 2023 (first author): Role of APR3 in cancer: apoptosis, autophagy, oxidative stress, and cancer therapy. PubMed 37634193
- Clin Chim Acta, 2022 (first author): Metagenomic next-generation sequencing for the diagnosis of fever of unknown origin in pediatric patients with hematological malignancy. PubMed 36283493
- Int J Lab Hematol, 2021 (first author): U2AF1 expression is a novel and independent prognostic indicator of childhood T-lineage acute lymphoblastic leukemia. PubMed 33314767
- Acta Biochim Pol, 2021 (senior author): Ginsenoside Rg3 suppresses ovarian cancer cell proliferation and invasion by inhibiting the expression of lncRNA H19. PubMed 34038042
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion